Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02629159 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
A Phase 3 study of Rheumatoid Arthritis, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 1,629
- Enrollment target
- 20
- Study locations
NCT02629159: Active Phase 3 study of Rheumatoid Arthritis, sponsored by AbbVie.
NCT02629159 is a Phase 3 study of Rheumatoid Arthritis that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 1,629 participants, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02629159, a Phase 3 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,629 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of methotrexate (MTX and who have an inadequate response to MTX.
Primary Outcome
The primary endpoint for United States (US)/Food and Drug Administration (FDA) regulatory purposes was ACR 20% response (ACR20) at Week 12. Participants who met the following 3 conditions for improvement from baseline were classified as meeting the ACR20 response criteria: 1. ≥ 20% improvement in 68-tender joint count; 2. ≥ 20% improvement in 66-swollen joint count; and 3. ≥ 20% improvement in at least 3 of the 5 following parameters: * Physician global assessment of disease activity * P
Conditions Studied
Interventions
- DRUG Adalimumab
- DRUG Upadacitinib
- DRUG Placebo for Upadacitinib
- DRUG Placebo for Adalimumab
Study Locations (20)
California
- Osteoporosis Medical Center /ID# 153935 - Beverly Hills
- T. Joseph Raoof, MD, Inc. /ID# 144884 - Encino
- Rheumatology Ctr of San Diego /ID# 153747 - Escondido
- C.V. Mehta MD, Med Corporation /ID# 143116 - Hemet
- Allergy and Rheum Med Clin /ID# 146083 - La Jolla
- Kotha and Kotha /ID# 161046 - La Mesa
- TriWest Research Associates- La Mesa /ID# 143115 - La Mesa
- Valerius Med Grp & Res Ctr /ID# 143120 - Los Alamitos
- Discovery MM Services, Inc /ID# 163504 - Los Angeles
- Desert Medical Advances /ID# 143097 - Palm Desert
Arizona
- AZ Arthritis and Rheum Assoc /ID# 143130 - Mesa
- SunValley Arthritis Center, Lt /ID# 143123 - Peoria
- Elite Clinical Studies, LLC /ID# 144881 - Phoenix
- AZ Arthritis and Rheum Researc /ID# 143080 - Phoenix
- AZ Arthritis and Rheum Researc /ID# 143121 - Phoenix
- AZ Arthritis & Rheuma Research /ID# 143131 - Phoenix
- Arizona Research Center, Inc. /ID# 144877 - Phoenix
- AZ Arthritis & Rheum Research /ID# 156093 - Sun City
- University of Arizona Cancer Center - North Campus /ID# 143114 - Tucson
Alabama
- Achieve Clinical Research, LLC /ID# 143136 - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,629 participants |
| Start Date | 2015-12-01 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 3 |
What the registry record for NCT02629159 still lists
NCT02629159 is an interventional study that assigns participants to a tested intervention. Its 1,629 participants enrollment target places it among the larger protocols in the corpus, below the 4,682-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 4 interventions - of which Adalimumab is the first listed.
NCT02629159 names 20 study sites across 3 states, led by California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT02629159 about?
NCT02629159 is a clinical study titled "A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate". The purpose of this study was to assess efficacy, including inhibition of radiographic progression, and safety with upadacitinib versus placebo and versus an active comparator, adalimumab, in adults with with moderately to severely active rheumatoid arthritis (RA) who are on a stable background of m...
What is the current status of trial NCT02629159?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,629 participants. The study started on 2015-12-01. Estimated completion is 2027-09-30.
What conditions does trial NCT02629159 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT02629159?
The interventions under investigation include: Adalimumab (DRUG), Upadacitinib (DRUG), Placebo for Upadacitinib (DRUG), Placebo for Adalimumab (DRUG).
Who is sponsoring clinical trial NCT02629159?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02629159 being conducted?
This trial has 20 study locations across Alabama, Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02629159's enrollment target sits among peer trials
1,629 13th of 197 higher than 185 of 197 other Rheumatoid Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06959524 · 1,616 participants · NA
AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI